Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Brenner Tumor 2Tongue Neoplasms 1Salivary Gland Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 25Carboplatin 22Taxes 16Bevacizumab 10Cisplatin 8Immunoglobulin G 7Disulfides 7Topotecan 3Platinum 3Docetaxel 31,2-diaminocyclohexaneplatinum II citrate 3paclitaxel poliglumex 2VTX-2337 2SS1(dsFv)PE38 2Peripheral Blood Stem Cell Transplantation 2Gemcitabine 2Filgrastim 2Etoposide 2Erlotinib Hydrochloride 2Chemotherapy, Adjuvant 2veliparib 1trioctyl phosphine oxide 1sargramostim 1pegfilgrastim 1liposomal doxorubicin 1emactuzumab 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Brenner Tumor × VTX-2337 × Clear all
NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Celgene

Phase 2 Completed
297 enrolled 15 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

NCT01294293 2014-12-25

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

GOG Foundation

Phase 1 Completed
20 enrolled
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡